Jefferies raises Nvidia stock price target to $205 on strong demand
In a recent transaction, Seely Lynn, the President and CEO of Lyell Immunopharma , Inc. (NASDAQ:LYEL), acquired 175,000 shares of the company’s common stock. The shares were purchased at a weighted average price of $0.6068 per share, amounting to a total investment of $106,190. The purchase comes as the stock trades near its 52-week low of $0.48, having declined over 76% in the past year. According to InvestingPro analysis, the company appears undervalued at current levels. The transaction, which took place on March 14, 2025, increases Lynn’s direct ownership to 712,500 shares.
The shares were bought at prices ranging from $0.59980 to $0.62020, as noted in a footnote accompanying the filing. This acquisition reflects Lynn’s continued confidence in the company’s prospects.
In other recent news, Lyell Immunopharma has been notified by Nasdaq of non-compliance with the minimum bid price requirement, as its stock has closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Lyell Immunopharma is considering measures such as a potential reverse stock split to address this issue, though success is not guaranteed. Meanwhile, H.C. Wainwright has maintained a Neutral rating on Lyell Immunopharma with a price target of $1.00, reflecting a cautious outlook. The firm is monitoring the development of Lyell’s IMPT-314, a candidate for treating large B-cell lymphoma, with upcoming data expected in mid-2025. Analysts are particularly interested in comparing this data against existing therapies like the Yescarta ZUMA-7 trial. The competitive landscape for new CAR-T therapies remains challenging, with high efficacy benchmarks set by current standard treatments. Investors are closely watching Lyell Immunopharma as it navigates these developments and potential Nasdaq delisting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.